- Richard Gonzalez, C.E.O. of AbbVie, told a congressional hearing that his pay was tied to the price of the company’s drug for rheumatoid arthritis and other conditions, Humira.
- The annual per-patient cost of Humira doubled between 2012 and 2018 to $38,000.
- In 2016 the $3.3 billion spent on the drug by Medicare and Medicaid accounted for 31 cents of every dollar spent on Humira in the U.S.
- A month’s supply of Truvada costs roughly $6 to make and sells for more than $1,600 in the United States.
- Truvada was developed largely with taxpayer dollars.
- Gilead has earned $36.2 billion on Truvada since 2004, according to its annual reports.
KEY TAKEAWAY: 71% of healthcare professionals believe that people with obesity are not interested in losing weight. “Obesity is one of the most complex, chronic health challenges faced by our society today, yet the current approach to obesity management falls short compared to other similar chronic diseases,” commented Professor Ian Caterson, ACTION IO lead investigator and foundation director of the Boden Institute at the University of Sydney.Continue reading
IN SUMMARY: I have been critical of big pharma because they keep their loyalty to Wall Street instead of patients. When the really good people within the industry learn to take risks and be heard the industry might change.Continue reading
- Facebook’s leaders seriously discussed selling access to user data — and privacy was an afterthought.
- Mark Zuckerberg oversaw plans to consolidate the social network’s power and control competitors by treating its users’ data as a bargaining chip, while publicly proclaiming to be protecting that data.
- Facebook ultimately decided not to sell the data directly but rather to dole it out to app developers who were considered personal “friends” of Zuckerberg or who spent money on Facebook and shared their own valuable data.
Three quartersof health information on Facebook was either misleading or included some false information. Only three were considered “highly credible.” Some lacked context of the issue, exaggerated the harms of a potential threat, or overstated research findings.
- Many articles never back claims with links to original sources or research studies to support findings.
- In terms of overall credibility, slightly less than half, of posts, achieved a high credibility rating. However, highly rated articles received 11 million shares, while poorly rated articles had roughly 8.5 million shares.
KEY TAKEAWAY: There is nothing worse than promising very sick or dying patients with false hope of a “miracle cure”. Yet, Forbes and other media outlets, like The Hill, have spread the story about a small team of Israeli scientists who are telling the world they will have the first “complete cure” for cancer within a year. And not only that, but they claim it will be brief, cheap and effective and will have no or minimal side-effects. This company is another Theranos?Continue reading